This stock should have been entering the NASDAQ with a huge...

This stock should have been entering the NASDAQ with a huge bang, with a MC of a billon dollars plus, instead of it will ‘limp’ in at least one quarter of that figure, huge disappointment and failure by the Company to realise its ‘alleged’ value.

That value, one billion plus is either justified or not, if not that is a fair ‘cop’, if unwarranted then the Company has hugely let down its investors.

For reflection: it’s earlier IP, CardioCel; Company maker or saviour?, most definitely company saviour, with FDA approval the following CR, from memory, was done at significantly higher level, that along with the Vaccine Phase11 progress, with Prof Fraser at the helm, is responsible for this Company’s current existence, despite allusions that that this past history hindered the progress of the Company commencing CodeRed, should have been full steam ahead with the ceasing of Vaccine funding, imo.

For reflection: will the Company’s current IP be a Company maker or follow suite as per the CardioCel IP?, Competitors have funded it’s IP to the tune of billions of dollars compared to the tenths of the investment Anteris have spent on its IP, it’s IP touted as breakthrough but seemingly hardly reflecting that value.

It has been said of how many stocks have listed on the NASDAQ,; again how many of them have the history of this Company: one that has a sp of one cent, the current sp inflated from two previous consolidations, and a record of sp decline despite the stellar progress of its IP, genuinely interested in stocks that have bucked that trend.

This Company is not the master of its sp and will have a huge challenge of being master of its final worth the way this stock is travelling and has travelled.

I do respect your pragmatic insights htae39, anything that bucks the usual confirmation bias and has substance.

Imho, not advice.